JP2019514955A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019514955A5 JP2019514955A5 JP2018557799A JP2018557799A JP2019514955A5 JP 2019514955 A5 JP2019514955 A5 JP 2019514955A5 JP 2018557799 A JP2018557799 A JP 2018557799A JP 2018557799 A JP2018557799 A JP 2018557799A JP 2019514955 A5 JP2019514955 A5 JP 2019514955A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- solvate
- salt
- substituent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662332541P | 2016-05-06 | 2016-05-06 | |
| US62/332,541 | 2016-05-06 | ||
| PCT/US2017/031297 WO2017192991A1 (en) | 2016-05-06 | 2017-05-05 | Selective estrogen receptor down-regulators (serds) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019514955A JP2019514955A (ja) | 2019-06-06 |
| JP2019514955A5 true JP2019514955A5 (enExample) | 2020-06-18 |
| JP7064772B2 JP7064772B2 (ja) | 2022-05-11 |
Family
ID=60203671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018557799A Active JP7064772B2 (ja) | 2016-05-06 | 2017-05-05 | 選択的エストロゲン受容体ダウンレギュレーター（ｓｅｒｄｓ） |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20190233442A1 (enExample) |
| EP (1) | EP3452486A4 (enExample) |
| JP (1) | JP7064772B2 (enExample) |
| CN (1) | CN109415388A (enExample) |
| WO (1) | WO2017192991A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017182493A1 (en) | 2016-04-20 | 2017-10-26 | Astrazeneca Ab | Indazole derivatives for use in down-regulation of the estrogen receptor for the treatment of cancer |
| US10149839B2 (en) | 2016-07-25 | 2018-12-11 | Astrazeneca Ab | Chemical compounds |
| EP3640251B1 (en) | 2016-10-24 | 2021-12-08 | Astrazeneca AB | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer |
| PL3494116T3 (pl) | 2017-01-30 | 2020-04-30 | Astrazeneca Ab | Modulatory receptora estrogenowego |
| IT201900004041A1 (it) * | 2019-03-20 | 2020-09-20 | Farmabios Spa | Procedimento per la preparazione di un derivato del fulvestrant |
| CN115667275B (zh) * | 2020-04-21 | 2024-02-23 | 南京再明医药有限公司 | 含硼化合物及其应用 |
| MX2022013391A (es) | 2020-04-24 | 2022-11-30 | Astrazeneca Ab | Pauta posologica para el tratamiento del cancer. |
| MX2022013258A (es) | 2020-04-24 | 2022-11-14 | Astrazeneca Ab | Formulaciones farmaceuticas. |
| IT202100008066A1 (it) * | 2021-03-31 | 2022-10-01 | Ind Chimica Srl | PROCESSO PER LA PREPARAZIONE DI ACIDO B-[(7α,17β)-17-IDROSSI-7-[9-[(4,4,5,5,5-PENTAFLUOROPENTIL)SULFINIL]NONIL]ESTRA-1,3,5(10)-TRIEN-3-IL]-BORONICO E INTERMEDI DEL PROCESSO |
| IT202100012062A1 (it) * | 2021-05-11 | 2022-11-11 | Ind Chimica Srl | PROCESSO PER LA PREPARAZIONE DI ACIDO B-[(7α,17β)-17-IDROSSI-7-[9-[(4,4,5,5,5-PENTAFLUOROPENTIL)SULFINIL]NONIL]ESTRA-1,3,5(10)-TRIEN-3-IL]-BORONICO E INTERMEDI DEL PROCESSO |
| CN113444134A (zh) * | 2021-07-22 | 2021-09-28 | 中国药科大学 | 雌甾-1,3,5(10)-三烯类化合物其制备方法和医药用途 |
| CH720542B1 (it) * | 2021-10-29 | 2025-09-15 | Ind Chimica Srl | PROCESSO PER LA PREPARAZIONE DI ACIDO Beta-[(7alpha,17beta)-17-IDROSSI-7-[9-[(4,4,5,5,5-PENTAFLUOROPENTIL)SULFINIL]NONIL]ESTRA-1,3,5(10)-TRIEN-3-IL]-BORONICO E INTERMEDI DEL PROCESSO |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999020646A1 (en) * | 1997-10-23 | 1999-04-29 | American Home Products Corporation | Estra-1,3,5(10)-triene-7alpha-thioethers |
| SE527131C2 (sv) * | 2004-02-13 | 2005-12-27 | Innoventus Project Ab | Steroider för cancerbehandling |
| WO2010107474A1 (en) * | 2009-03-16 | 2010-09-23 | The Research Foundation Of State University Of New York | Antiestrogens for breast cancer therapy |
| US10112962B2 (en) * | 2014-07-02 | 2018-10-30 | Xavier University | Boron-based prodrug strategy for increased bioavailability and lower-dosage requirements for drug molecules containing at least one phenol (or aromatic hydroxyl) group |
-
2017
- 2017-05-05 US US16/317,196 patent/US20190233442A1/en not_active Abandoned
- 2017-05-05 EP EP17793447.8A patent/EP3452486A4/en not_active Withdrawn
- 2017-05-05 JP JP2018557799A patent/JP7064772B2/ja active Active
- 2017-05-05 CN CN201780027863.XA patent/CN109415388A/zh active Pending
- 2017-05-05 WO PCT/US2017/031297 patent/WO2017192991A1/en not_active Ceased